MCK · CIK 927653
What McKesson Corporation told the SEC could break it.
McKesson's disclosures lead with extreme customer concentration in its pharmaceutical-distribution model: its ten largest customers, including group purchasing organizations, were about 73% of fiscal 2026 revenue and 43% of trade receivables, with CVS Health alone at roughly 24% — so the loss or distress of a top customer carries outsized revenue and credit risk. Its business is also shaped by drug-pricing policy, including the Inflation Reduction Act's Medicare price negotiation, inflation rebates and Part D cost cap, plus the December 2025 expiry of the ACA's enhanced subsidies. As a distributor it depends on third-party suppliers' continued ability to provide products, and its working-capital-intensive model is sensitive to credit conditions that could cause customers to delay payments or suppliers to raise prices or cut output.
4 self-disclosed vulnerabilities, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Customer concentration
- top-10 customers (incl. GPOs) = 73% of revenue; CVS = 24%; 43% of trade receivableshigh
In fiscal 2026, McKesson's ten largest customers (including group purchasing organizations) accounted for ~73% of total consolidated revenues and ~43% of total trade accounts receivable, with its single largest customer CVS Health at ~24% — extreme customer/credit concentration in the North American Pharmaceutical segment.
“During fiscal 2026, sales to the Company's ten largest customers, including group purchasing organizations (“GPOs”), accounted for approximately 73 % of its total consolidated revenues and approximately 43 % of total trade accounts receivable at March 31, 2026.”
SEC filing →As of 2026
Regulatory & policy
- IRA Medicare drug-price negotiation/inflation rebate/Part D cap + ACA enhanced-subsidy expiry (Dec 31, 2025)medium
The IRA authorizes Medicare drug-price negotiation for certain Part B/D drugs, an inflation-rebate program and a Part D patient cost-sharing cap (all aimed at lowering drug prices), and the ACA's enhanced premium subsidies expired December 31, 2025 — changes that could reduce coverage and impact McKesson's customers and business.
“Three central features of the IRA have authorized the government to negotiate drug prices for certain Medicare Part B and Medicare Part D drugs over time, establish an inflation rebate program, and cap patient cost sharing under Medicare Part D.”
Sole-source dependency
- dependence on third-party suppliers for pharmaceutical and other product supply; sourcing disruptionsmedium
McKesson relies on third parties for the supply of pharmaceutical and other products and is subject to its suppliers' continued ability to supply required products; from time to time it experiences difficulties and delays in sourcing and selling products due to various causes.
“We rely on third parties for the supply of pharmaceutical and other products, and our operations are subject to our suppliers' continued ability to supply the products that we require. From time to time, we experience difficulties and delays in sourcing and selling products due to a variety of causes”
SEC filing →As of 2026
Liquidity & debt
- credit-market sensitivity of customers and suppliers (payment delays, supplier price/output changes)low
Limited availability of credit or interest-rate/capital-market changes could lead McKesson's customers to reduce purchases or delay/fail payments, and its suppliers to raise prices, cut output, change sale terms, or be unable to make payments owed to McKesson (fees, returns, incentives) — straining its working-capital-intensive distribution model.
“Suppliers might increase their prices, reduce their output, or change their terms of sale due to limited availability of credit. Suppliers might be unable to make payments due to us for fees, returned products, or incentives.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings — including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
“Sales to our largest customer, CVS Health Corporation (“CVS”), accounted for approximately 24% of our total consolidated revenues in fiscal 2026.”
Cited →
Its suppliers
“For the year ended December 31, 2025, our four largest customers, Cencora, Inc., McKesson Drug Co., Cardinal Health, Inc., and CVS Health Corporation, collectively accounted for approximately 71% of our consolidated net revenue.”
Cited →“approximately 90% of our gross product sales in the U.S. have been to three large wholesalers—Cardinal Health, Inc., Cencor[a], ... McKesson Corporation”
Cited →“The following summarizes revenue, as a percentage of Total revenues , from our three largest U.S. wholesaler customers, which was concentrated in our Biopharma operating segment: Year Ended December 31, 2025 2024 2023 McKesson, Inc. 25 % 23 % 16 % Cencora, Inc. 16 % 17 % 12 % Cardinal Health, Inc. 13 % 14 % 10 %”
Cited →“In the year ended December 31, 2024, sales to McKesson Corporation and Medline Industries accounted for approximately 18% and 17% of consolidated net sales, respectively.”
Cited →“As of December 31, 2024, five customers accounted for 80 % of gross accounts receivable, including ESSDS, which accounted for 39 % of gross accounts receivable, ASD, which accounted for 15 % of gross accounts receivable and McKesson, which accounted for 13 % of gross accounts receivable.”
Cited →“al Health, Inc. and Cencora, Inc.) accounted for substantially all of AbbVie's pharmaceutical product sales in the United States. No individual wholesaler accounted for greater than 43% of AbbVie's 2025 gross revenues in the United States.”
Cited →“Our product sales to three large wholesalers, McKesson Corporation, Cencora, Inc. and Cardinal Health, Inc., each individually accounted for more than 10% of total revenues for each of the years 2025, 2024 and 2023. On a combined basis, these wholesalers accounted for 77%, 77% and 79% of worldwide gross revenue”
Cited →“for the fiscal year ended September 30, 2025, gross sales to Cencora, McKesson Corporation, and Cardinal Health, Embecta's three largest distributors, together represented approximately 42% of Embecta's worldwide gross sales.”
Cited →“The following table summarizes revenues from each of our customers who individually accounted for 10% or more of the total net product sales and revenues from collaborations: Year Ended December 31, 2025 2024 McKesson Corporation 42% 45%”
Cited →“McKesson Plasma and Biologics * * * * 14 % Cardinal Health * * * * 10 % U.S. Government (1) * * 43 %”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch